<DOC>
	<DOC>NCT01192919</DOC>
	<brief_summary>Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.</brief_summary>
	<brief_title>Tumour Registry Lung Cancer (TLK)</brief_title>
	<detailed_description>The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy written informed consent start of neoadjuvant, adjuvant or firstline therapy no longer than 4 weeks before informed consent patients not receiving any systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bronchial carcinoma</keyword>
	<keyword>registry</keyword>
	<keyword>real life treatment</keyword>
	<keyword>cohort study</keyword>
	<keyword>NSCLC</keyword>
	<keyword>SCLC</keyword>
	<keyword>Germany</keyword>
</DOC>